IL274125B - Exosomes comprising rna therapeutics - Google Patents

Exosomes comprising rna therapeutics

Info

Publication number
IL274125B
IL274125B IL274125A IL27412520A IL274125B IL 274125 B IL274125 B IL 274125B IL 274125 A IL274125 A IL 274125A IL 27412520 A IL27412520 A IL 27412520A IL 274125 B IL274125 B IL 274125B
Authority
IL
Israel
Prior art keywords
binding
polypeptide
evs
binding domain
population
Prior art date
Application number
IL274125A
Other languages
English (en)
Hebrew (he)
Other versions
IL274125A (en
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL274125(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of IL274125A publication Critical patent/IL274125A/en
Publication of IL274125B publication Critical patent/IL274125B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL274125A 2017-11-08 2018-11-08 Exosomes comprising rna therapeutics IL274125B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1718471.4A GB2568255A (en) 2017-11-08 2017-11-08 Exosomes comprising RNA therapeutics
PCT/EP2018/080681 WO2019092145A1 (en) 2017-11-08 2018-11-08 Exosomes comprising rna therapeutics

Publications (2)

Publication Number Publication Date
IL274125A IL274125A (en) 2020-06-30
IL274125B true IL274125B (en) 2022-07-01

Family

ID=60664781

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274125A IL274125B (en) 2017-11-08 2018-11-08 Exosomes comprising rna therapeutics

Country Status (18)

Country Link
US (1) US20210369865A1 (https=)
EP (2) EP3706796B1 (https=)
JP (2) JP7077404B2 (https=)
KR (1) KR102431418B1 (https=)
CN (1) CN111629760B (https=)
AU (1) AU2018365299B2 (https=)
BR (1) BR112020006960A2 (https=)
CA (1) CA3082194C (https=)
DK (1) DK3706796T3 (https=)
ES (1) ES2899857T3 (https=)
GB (1) GB2568255A (https=)
IL (1) IL274125B (https=)
MX (1) MX389425B (https=)
PT (1) PT3706796T (https=)
RU (1) RU2020118554A (https=)
SG (1) SG11202004199PA (https=)
WO (1) WO2019092145A1 (https=)
ZA (1) ZA202002537B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019122461A (ja) * 2018-01-12 2019-07-25 株式会社三洋物産 遊技機
JP2019122462A (ja) * 2018-01-12 2019-07-25 株式会社三洋物産 遊技機
JP2019136400A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136401A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136398A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136399A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
FR3081169B1 (fr) * 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
GB201810301D0 (en) * 2018-06-22 2018-08-08 Evox Therapeutics Ltd Combinatorial gene therapy
GB201906482D0 (en) * 2019-05-08 2019-06-19 Evox Therapeutics Ltd Exosome comprising stabilized RNA therapeutics
WO2021095842A1 (ja) * 2019-11-15 2021-05-20 国立大学法人 東京大学 バーコード化された細胞外小胞のライブラリー
WO2021172595A1 (ja) * 2020-02-28 2021-09-02 国立大学法人金沢大学 抗原提示細胞外小胞、それを含む組成物、及びそれらを製造するための方法
KR20210116324A (ko) 2020-03-12 2021-09-27 기초과학연구원 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법
CN111424017B (zh) * 2020-03-27 2022-08-09 暨南大学 一种装载shRNA的外泌体及其构建方法与应用
WO2021207126A1 (en) * 2020-04-06 2021-10-14 The Trustees Of Dartmouth College Compositions and methods for treating bacterial infections
WO2021223659A1 (en) * 2020-05-06 2021-11-11 Nanjing Iaso Biotherapeutics Co., Ltd. Extracellular vesicles targeting cancer cells and uses thereof
WO2021231854A1 (en) * 2020-05-14 2021-11-18 Modernatx, Inc. Lnp compositions comprising an mrna therapeutic and an effector molecule
CN111647045B (zh) * 2020-06-17 2022-05-27 清华大学深圳国际研究生院 一种cd133拮抗多肽及其衍生物与应用
GB202010278D0 (en) 2020-07-03 2020-08-19 Evox Therapeutics Ltd Extracellular vesicles with improved half-life
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112626068B (zh) * 2020-12-21 2021-12-03 徐州医科大学 一种靶向Notch1基因的LncRNA及其应用
CN115137835A (zh) * 2021-03-30 2022-10-04 南京大学 一种用于治疗结肠炎的rna递送系统
GB202105925D0 (en) 2021-04-26 2021-06-09 Evox Therapeutics Ltd Modified extracellular vesicles (EVs) with improved half-life
JP2024528547A (ja) * 2021-06-30 2024-07-30 プリモリス セラピューティクス カンパニー リミテッド アンチセンスオリゴヌクレオチドに基づく薬物が搭載された細胞由来の自然又は人工ナノベシクルを含有する薬学組成物
WO2023284380A1 (zh) * 2021-07-15 2023-01-19 呈诺再生医学科技(北京)有限公司 细胞作为基因治疗的载体在临床中的应用
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
US20240360198A1 (en) * 2021-09-01 2024-10-31 National University Corporation Kanazawa University Immunoregulatory method, nucleic acid composition for immunoregulation, and use thereof
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
CN114569721B (zh) * 2022-02-25 2023-03-24 浙江大学 载药的胞外囊泡在制备治疗肥胖或减轻肥胖相关代谢指标的药物中的应用
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
GB202210861D0 (en) * 2022-07-25 2022-09-07 Univ Oxford Innovation Ltd Loaded extracellular vesicle
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024112359A1 (en) * 2022-11-21 2024-05-30 The Johns Hopkins University Genetic enhancement of exosome production
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
WO2024194423A1 (en) 2023-03-23 2024-09-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their use for vaccines and for immunomodulation
WO2024230738A1 (zh) * 2023-05-08 2024-11-14 天津外泌体科技有限公司 外囊泡融合蛋白及其应用
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
WO2025068572A2 (en) 2023-09-29 2025-04-03 Evox Therapeutics Limited Polypeptides comprising inteins for engineered evs
CN120393034A (zh) * 2023-11-10 2025-08-01 深圳市茵冠生物科技有限公司 一种寡核苷酸偶联物及含其外泌体偶联物与应用
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025196641A1 (ru) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Гибридные частицы, способ их получения и применение
WO2025247999A1 (en) 2024-05-30 2025-12-04 Conveyxo Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles
EP4656187A1 (en) 2024-05-30 2025-12-03 ConvEyXo Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
MX2012013037A (es) * 2010-05-10 2013-07-29 Univ California Composiciones de endorribonucleasa y metodos de uso de las mismas.
WO2013188638A2 (en) * 2012-06-15 2013-12-19 The Regents Of The University Of California Endoribonucleases and methods of use thereof
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
JP7103750B2 (ja) * 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
EP3858992A1 (en) * 2015-03-13 2021-08-04 The Jackson Laboratory A three-component crispr/cas complex system and uses thereof
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
EP3440090B1 (en) * 2016-04-06 2022-09-28 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US20210054404A1 (en) * 2017-08-22 2021-02-25 Napigen, Inc. Organelle genome modification using polynucleotide guided endonuclease

Also Published As

Publication number Publication date
CA3082194A1 (en) 2019-05-16
KR20200086322A (ko) 2020-07-16
KR102431418B1 (ko) 2022-08-16
WO2019092145A1 (en) 2019-05-16
JP2021507682A (ja) 2021-02-25
RU2020118554A3 (https=) 2022-04-20
EP3706796A1 (en) 2020-09-16
JP7077404B2 (ja) 2022-05-30
ES2899857T3 (es) 2022-03-15
ZA202002537B (en) 2022-07-27
GB2568255A (en) 2019-05-15
MX2020004698A (es) 2022-01-17
JP2022113690A (ja) 2022-08-04
CN111629760A (zh) 2020-09-04
PT3706796T (pt) 2021-11-24
SG11202004199PA (en) 2020-06-29
RU2020118554A (ru) 2021-12-08
GB201718471D0 (en) 2017-12-20
EP3706796B1 (en) 2021-09-29
DK3706796T3 (da) 2021-11-22
US20210369865A1 (en) 2021-12-02
CA3082194C (en) 2022-10-04
CN111629760B (zh) 2023-09-05
AU2018365299B2 (en) 2021-12-16
EP3973989A1 (en) 2022-03-30
IL274125A (en) 2020-06-30
BR112020006960A2 (pt) 2020-10-13
MX389425B (es) 2025-03-20
AU2018365299A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
IL274125B (en) Exosomes comprising rna therapeutics
JP2021507682A5 (https=)
RU2018145738A (ru) Экзосомы, содержащие терапевтические полипептиды
JP2019520852A5 (https=)
JP2019524745A5 (https=)
AU2016362129A1 (en) Compositions and methods for immunooncology
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
EP3965828B1 (en) Exosome comprising stabilized rna therapeutics
US20210386868A1 (en) Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
US20240382521A1 (en) Methods of engineering immune cells having reduced fratricidal activity
CN109021114B (zh) 联合两种单链抗体的双特异性嵌合抗原受体及表达载体
CN115925948A (zh) 一种抗cd22纳米抗体及其应用
EP4561536A1 (en) Loaded extracellular vesicle
CN110331134B (zh) 一种表达抗原识别区域的通用型细胞治疗产品及其制备方法和应用
US10428307B2 (en) Method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors
CN113549157B (zh) 双靶向嵌合抗原受体及其应用
US20250288695A1 (en) Tspan2 as scaffold protein for engineered extracellular vesicles
EP0122814A3 (en) A method of cotransformation, cotransformed mouse cells producing at their surface human class ii antigens and the use of those cells to generate mouse hybridomas that produce monoclonal antibodies to those antigens
CN115925940B (zh) 特异性结合cd47的抗体、其重组溶瘤病毒及其用途
KR20260045724A (ko) 엑소좀의 생산 및 이의 용도
WO2026093377A1 (en) Crispr rna molecules for improved ev-mediated delivery of cas12 rnp complexes
CN121610563A (zh) 一种TCR mRNA快速合成方法及其应用
RU2022117055A (ru) Химерные антигенные рецепторы и пути их применения
CN116675773A (zh) 一种抗mxr7抗体及其应用
CN116063471A (zh) 一种抗冠状病毒rbd蛋白的抗体及其应用